CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $49,763 | -22.8% | 1,096,354 | -4.5% | 0.08% | -18.3% |
Q2 2023 | $64,445 | +23.2% | 1,147,929 | -0.8% | 0.10% | +14.3% |
Q1 2023 | $52,323 | +8.3% | 1,156,810 | -2.7% | 0.09% | -6.2% |
Q4 2022 | $48,305 | -99.9% | 1,188,321 | -4.6% | 0.10% | -41.2% |
Q3 2022 | $81,374,000 | -4.1% | 1,245,199 | -10.8% | 0.16% | +5.1% |
Q2 2022 | $84,850,000 | +4.7% | 1,396,258 | +8.2% | 0.16% | +45.4% |
Q1 2022 | $81,030,000 | -18.8% | 1,290,905 | -1.9% | 0.11% | -10.7% |
Q4 2021 | $99,736,000 | -3.8% | 1,316,123 | +42.1% | 0.12% | -4.7% |
Q3 2021 | $103,638,000 | -29.5% | 925,914 | +1.9% | 0.13% | -28.7% |
Q2 2021 | $147,101,000 | – | 908,652 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |